Início › Leucemia Bifenotípica Aguda › Oklahoma

Ensaios clínicos de Leucemia Bifenotípica Aguda em Oklahoma

5 estudos para Leucemia Bifenotípica Aguda estão buscando participantes em locais em Oklahoma.

Cidades em Oklahoma

Texto oficial do estudo (Inglês)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

University of Oklahoma Health Sciences Center, Oklahoma City

RecrutandoFase 2

365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

University of Oklahoma Health Sciences Center, Oklahoma City
Saint Francis Children's Hospital, Tulsa

RecrutandoFase 3

365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

University of Oklahoma Health Sciences Center, Oklahoma City

RecrutandoFase 1/2

Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Saint Francis Children's Hospital, Tulsa

RecrutandoFase 2

Idades de 1 a 18 · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT06390319

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Saint Francis Children's Hospital, Tulsa

RecrutandoFase 4

Idades de 1 a 18 · Todos os sexos · Atualizado em 14 de jul. de 2026 · NCT06289673

Fonte: ClinicalTrials.gov, dados obtidos em 2 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.